When it comes to the diabetes space, Dexcom is one of the heavy hitters. Its work in the continuous glucose monitoring space has put it on the map. In 2018, its Dexcom G6, an integrated continuous ...

These healthcare stocks have long-term and profitable growth runways.

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), and Verily, an Alphabet company, announced an amendment to the Collaboration and License ...

DexCom's Q3 performance shows impressive organic growth rates and increased revenue guidance for 2023. The company's strategic focus on international markets and expanding customer bases indicates ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...

Dexcom posted FY19 sales expectations on Monday and they are even better than the company forecast in Q3 at $1.47bn - a 42% year-on-year increase. Company drove revenues by 49% year-on-year in Q3 to ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

DexCom, Inc. DXCM shares are trading higher by 3.75% to $79.05 Thursday afternoon. Leerink Partners initiated coverage on the stock with an Outperform rating and a $110 price target. DexCom is ...

Investors have a few questions as the company faces increasing competition. As the adage goes, two things in life are inevitable: death and taxes. Experienced growth investors might want to add a ...